Group 1 - The Hang Seng Technology Index increased by 1.93% and the Hang Seng Index rose by 1.32% [1] - Notable stock performances include: Zhaoyi Innovation up by 45.06%, Dali Group Holdings up by 13.35%, and Rongchang Bio up by 8.84% [1] - Declining stocks include: Times Angel down by 4.96%, Master Kong Holdings down by 4.18%, and CIMC Enric down by 3.72% [1]

Core Viewpoint - Erythropoietin (EPO) is a glycoprotein hormone crucial for red blood cell production, primarily secreted by the kidneys, with significant implications for treating various types of anemia, particularly in chronic kidney disease (CKD) patients [1][2][4]. Group 1: EPO Drug Overview - EPO is essential for stimulating red blood cell production and regulating oxygen supply in the body, with applications in treating renal anemia, chemotherapy-related anemia, anemia in premature infants, and perioperative red blood cell mobilization [4][5]. - The global prevalence of CKD has significantly increased, with 156 million cases reported in China in 2023, up from 75.42 million in 1990, highlighting the growing public health challenge [6][7]. Group 2: Market Dynamics - The Chinese EPO drug market is projected to decline from 30 billion yuan in 2024 to 31 billion yuan in 2025, before recovering to 37 billion yuan by 2030, with a compound annual growth rate (CAGR) of 3.6% from 2025 to 2030 [7][9]. - Economic factors and healthcare limitations have resulted in unmet needs for renal anemia and other related conditions, suggesting a rising demand for EPO as healthcare access improves [9]. Group 3: Competitive Landscape - The EPO market in China is concentrated, with the top three companies holding 56.1% market share in 2024, led by Sangamo Therapeutics with over 30% market share, followed by Kexing Pharmaceutical at 16.7% [10]. - As of 2025, there are 79 EPO products approved in China, with significant competition among domestic companies, although many remain focused on first-generation EPO products rather than advancing to second-generation long-acting formulations [10].

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The company plans to conduct foreign exchange derivative trading in 2026 to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a total trading limit not exceeding 75 million RMB or equivalent foreign currency [4][10]. - The trading will primarily utilize the company's own funds and will not involve raised funds [5][6]. - The company will employ simple and transparent foreign exchange derivative instruments, such as forward contracts and options, with a maximum duration of 12 months [6][8]. Group 2 - The company has approved the use of up to 150 million RMB of temporarily idle raised funds for cash management, focusing on safe and liquid investment products with a maturity of no more than 12 months [21][24]. - The investment aims to enhance the efficiency of raised fund usage while ensuring that it does not affect the ongoing projects funded by these raised funds [23][38]. - The company will strictly control risks associated with these investments and will not use the funds for speculative purposes [35][50]. Group 3 - The company plans to provide a maximum guarantee of 320 million RMB for its subsidiaries' bank loans in 2026, which will enhance financing efficiency [53][60]. - The guarantee is based on the current business situation and is expected to be within a controllable risk range [54][61]. - The company has no overdue guarantees or litigation-related guarantees, ensuring a stable financial position [62]. Group 4 - The company anticipates daily related transactions with specific affiliated companies, with a total expected amount not exceeding 18.5 million RMB for 2026 [67][70]. - These transactions are necessary for the company's normal business operations and are conducted at market prices to ensure fairness [75][76]. - The company has established contracts with related parties to ensure compliance and protect shareholder interests [73][74]. Group 5 - The company intends to apply for a financing limit of up to 300 million RMB from banks and financial institutions in 2026, using its own assets as collateral [78][79]. - This financing is aimed at meeting the operational funding needs of the company and its subsidiaries without adversely affecting business operations [80].

格隆汇1月4日丨科兴制药(688136.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份131.93万股，占公司目前总股本比例为0.66%，回购成交的最 高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18万元(不含交易佣金等费 用)。 ...

Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]

证券日报网讯 1月4日，科兴制药发布公告称，截至2025年12月31日，公司通过上海证券交易所交易系 统以集中竞价交易方式已累计回购公司股份1，319，333股，占公司目前总股本比例为0.66%，回购成 交的最高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4，924.18万元（不含交易佣 金等费用）。 （编辑 王江浩） ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-008 重要内容提示： 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司 2025 年 5 月 8 日召开第二届董事会第二十四次会议审议通过了《关于调 整回购股份价格上限的议案》，将回购股份价格上限调整为人民币 46.83 元/股（含）。 具体内容详见公司于2025年5月9日披露在上海证券交易所网站（www.sse.com.cn） 的《关于调整回购股份价格上限的公告》（公告编号：2025-024）。 鉴于公司 2024 年年度权益分派已实施完毕，公司以集中竞价交易方式回购股 份价格上限由不超过人民币46.83元/股（含）调整为不超过人民币46.75元/股（含）。 具 体 内 容 详 见 公 司 于 2025 年 6 月 21 日 披 露 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《关于 2024 年年度权益分派实施后调整回购价格上限的公 告》（公告编号：20 ...

Core Viewpoint - Sinovac has been awarded the exclusive contract to supply over 8 million doses of flu vaccine to the Chilean government for the 2026 fiscal year, reinforcing its position in the market and demonstrating its product quality and international compliance capabilities [1] Group 1: Contract and Supply Details - The first batch of vaccines is scheduled to arrive in Chile by the end of January 2026 to meet the upcoming flu season's demand [1] - Sinovac has been the sole supplier of flu vaccines in Chile for two consecutive years, indicating a strong recognition from the Chilean public health system [1] Group 2: Previous Performance - In 2025, Sinovac supplied over 8.3 million doses of flu vaccine in Chile, achieving approximately 80% vaccination coverage of the target population [1]

格隆汇12月31日丨科兴制药(688136.SH)公布，在保证不影响公司募集资金投资计划正常进行的前提 下，公司及全资子公司拟使用最高不超过人民币1.5亿元（包含本数）的暂时闲置募集资金进行现金管 理，额度使用期限为自董事会审议通过之日起12个月内有效。在前述额度及期限范围内，资金可以循环 滚动使用。 ...